Please Wait
Applying Filters...
menu
    • menu
    DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

    Virtual Booth

    Contact Supplier

    Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    With Fermion, start the journey of your innovative API.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Bosutinib Monohydrate

    ACTIVE PHARMA INGREDIENTS

    FINISHED DOSAGE FORMULATIONS

    DRUG PRODUCT COMPOSITIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 5,432Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial
    Novartis' asciminib bests Pfizer's Bosulif in phase 3 leukemia trial

    27 Aug 2020

    // Nick P.Taylor FIERCE BIOTECH

    https://www.fiercebiotech.com/biotech/novartis-asciminib-bests-pfizer-s-bosulif-phase-3-leukemia-trial

    Nick P.Taylor FIERCE BIOTECH
    27 Aug 2020
    Share Share
    EMA’s CHMP Recommends Five New Medicines for Approval
    EMA’s CHMP Recommends Five New Medicines for Approval

    26 Feb 2018

    // Ana Mulero RAPS

    https://www.raps.org/news-and-articles/news-articles/2018/2/ema%E2%80%99s-chmp-recommends-five-new-medicines-for-appro?utm_source=Email&utm_medium=Informz&utm_campaign=Informz-Emails&_zs=VHOsL1&_zl=k7BK4

    Ana Mulero RAPS
    26 Feb 2018
    Share Share
    First-line use of Pfizer’s Bosulif cleared in the US
    First-line use of Pfizer’s Bosulif cleared in the US

    21 Dec 2017

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/first-line_use_of_pfizers_bosulif_cleared_in_the_us_1214830

    Selina McKee PHARMA TIMES
    21 Dec 2017
    Share Share
    Pfizer, Avillion file for Bosulif expansion
    Pfizer, Avillion file for Bosulif expansion

    31 Aug 2017

    // Selina McKee PHARMA TIMES

    http://www.pharmatimes.com/news/pfizer,_avillion_file_for_bosulif_expansion_1203702

    Selina McKee PHARMA TIMES
    31 Aug 2017
    Share Share
    Pfizer's Ibrance faces tough review at NICE, U.K. exec worries
    Pfizer's Ibrance faces tough review at NICE, U.K. exec worries

    28 Nov 2016

    // Eric Sagonowsky FIERCE PHARMA

    http://www.fiercepharma.com/pharma/pfizer-s-ibrance-combo-faces-tough-review-at-nice-exec-worries

    Eric Sagonowsky FIERCE PHARMA
    28 Nov 2016
    Share Share
    Eisai Latest Cancer Drugmaker to Win UK Approval After Price Cut
    Eisai Latest Cancer Drugmaker to Win UK Approval After Price Cut

    03 Nov 2016

    // Ben Hirschler REUTERS

    http://www.reuters.com/article/us-health-cancer-britain-idUSKBN12Y004

    Ben Hirschler REUTERS
    03 Nov 2016
    Share Share